Navigation Links
Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.
Date:12/18/2007

rence, or RNAi, is a cellular mechanism that can be used to turn off the production of a protein by using small interfering RNAs (siRNAs). siRNAs are double-stranded RNA molecules that are able to silence a gene in a sequence-specific manner by degradation of the target messenger RNA. In the case of an siRNA directed against influenza, the target is one or more genes that encode proteins critical for viral replication. If siRNAs are successful at turning off the production of such proteins, the spread of infection would be prevented or slowed. Nastech's RNAi research and development programs seek to develop safe and effective therapeutics by identifying key protein targets, designing the siRNA that will turn off the production of the targeted proteins, and developing a formulation for the delivery of this potential new class of therapeutics.

About Nastech

Nastech is a biopharmaceutical company developing innovative products based on proprietary molecular biology-based drug delivery technologies. Nastech and our collaboration partners are developing products for multiple therapeutic areas including osteoporosis, obesity, diabetes, autism, respiratory diseases and inflammatory conditions. Additional information about Nastech is available at http://www.nastech.com.

About MDRNA, Inc.

MDRNA, a company developing innovative products based on RNA-based technologies, is a wholly-owned subsidiary of Nastech. Discovery of the biological process of RNA interference (RNAi) garnered the Nobel Prize in Medicine in 2006, and holds tremendous potential as a basis for human therapeutics. Nastech began work on RNAi in 2002 and has assigned its intellectual property, as it relates to the development of RNA-based therapeutics, to MDRNA in order to bring greater focus on the development of RNA-based technologies and enhance shareholder value arising from this exciting new field. Additional information about M
'/>"/>

SOURCE Nastech Pharmaceutical Company Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Nastech to Host 2007 Analyst and Institutional Investor Day
2. Nastech to Release Third Quarter Financial Results and Host Webcast on Monday, October 29, 2007
3. Nastech Announces Third Quarter 2007 Financial Results
4. Nastech to Present at Acumen BioFin Rodman & Renshaw Healthcare Conference
5. Nastech to Present at BMO Capital Markets Focus on Healthcare Conference
6. Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding
7. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
8. New property found in ancient mineral lodestone
9. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
10. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
11. Verenium Advances Its Development Work With Cargill on a New Food-Related Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... Arthur Kay , the 23-year-old British founder of environmentally ... Challenge 2014. The jury, chaired by Ellen MacArthur ... final in Amsterdam to realize ... uses a patented process to upcycle waste coffee grounds ... used for powering buildings and transport systems. Bio-bean is ...
(Date:9/12/2014)... LONDON , September 12, 2014 ... 4,591.81, up 0.12%, the Dow Jones Industrial Average finished the ... at 1,997.45, up 0.09%. The gains were broad based as ... The S&P 500 Health Care Sector Index ended the day ... in the last one month. Investor-Edge has initiated coverage on ...
(Date:9/11/2014)... team of Berkeley Lab researchers believes it has ... of single atomic layers of transition metal dichalcogenide ... promise for nanoelectronic and photonic applications. , ... of tungsten disulfide, one of the most promising ... existence of excitonic dark states energy states ...
(Date:9/11/2014)... -- XBiotech announced today it has taken delivery on ... says will be used to dramatically increase its fill ... fill, stopper and crimp vials, which is the final ... said to contain an in-line feed back loop and ... of quality compared to less sophisticated filling systems. The ...
Breaking Biology Technology:Green Startup Bio-Bean Wins $680,000 in Postcode Lottery Green Challenge 2Green Startup Bio-Bean Wins $680,000 in Postcode Lottery Green Challenge 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 4Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 5Excitonic dark states shed light on TMDC atomic layers 2Excitonic dark states shed light on TMDC atomic layers 3
... Enanta Pharmaceuticals, Inc. announced today that its lead ... inhibitor program, EDP-239, has been recognized on Windhover,s list ... to Watch." EDP-239 was chosen by independent experts at ... a clinically-validated target, is a non-structural viral protein that ...
... at deCODE Genetics and academic collaborators from Iceland, The Netherlands, ... today report the discovery of a variant in the sequence ... cell carcinoma of the skin (BCC), as well as prostate ...  The study was done in collaboration with Illumina, Inc., and ...
... Sept. 23, 2011 Citizens Bank today announced that ... a major expansion by The Wistar Institute that includes ... historic facility at 36th and Spruce streets in University ... an international leader in basic biomedical research, particularly cancer ...
Cached Biology Technology:Enanta's Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhover's Top 10 Infectious Disease Projects to Watch 2Enanta's Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhover's Top 10 Infectious Disease Projects to Watch 3deCODE genetics, Together with Academic Collaborators and Illumina, Discovers Genetic Risk Factor for Skin, Prostate and Brain Cancers 2deCODE genetics, Together with Academic Collaborators and Illumina, Discovers Genetic Risk Factor for Skin, Prostate and Brain Cancers 3Citizens Bank Provides $70 Million in Financing Toward $100 Million Expansion of The Wistar Institute 2
(Date:9/12/2014)... come under attack from a pathogen, they sometimes respond ... the attack, committing "cell suicide" to thwart further damage ... small, often microscopic, spots or lesions on the plant. ... understand how the plant regulates this "spotty" defense mechanism ... Researchers at North Carolina State University have identified a ...
(Date:9/12/2014)... and POINT ROBERTS, Washington , September 12, ... http://www.investorideas.com ) a global news source covering leading sectors including ... on the September 9 th launch of Apple Pay, ... Intelligence, Janice Kephart , founder of the Secure Identity ... of NXT-ID, Inc, (NASDAQ: NXTD ) a company ...
(Date:9/11/2014)... Amsterdam, NL, 11 September 2014 Patients with ... preparation and ingestion, which could contribute to poor ... Published studies have also suggested that PD is ... control groups. A report published in the ... in patients with mild-to-moderate PD, finding that the ...
Breaking Biology News(10 mins):Corn spots: Study finds important genes in defense response 2Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 2Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 3Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 4Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 5Few mild-to-moderate Parkinson's disease patients suffer from malnutrition, yet almost one-third are at risk 2
... Study of Hepatitis C (PEDS-C) trial reveals that children ... display significant changes in height, weight, body mass index ... issue of Hepatology , a journal of the ... that most growth-related side effects are reversible with cessation ...
... New Rochelle, NY, August 9, 2012Despite criticism from Congressional ... its Rim of the Pacific (RIMPAC) 2012 international maritime ... 50% biofuels blend. The Navy contends that renewable energy ... play in enhancing national security and energy independence. Tom ...
... University researchers are teaming up with Coastal Carolina University ... along the Savannah River to gather data for the ... and transmit real-time information about the quality and quantity ... project leaders Gene Eidson, director of Clemson,s Institute of ...
Cached Biology News:Height, weight and BMI changes seen in children treated with peginterferon alpha for hepatitis C 2US Navy defends renewable fuels strategy in Industrial Biotechnology Journal 2Clemson, Coastal Carolina universities to set hundreds of sensors in Savannah River 2
Recognizes the VZV nucleocapsid by indirect immunofluorescence and immunoprecipitation. Shows cross-reactivity to HSV....
Duck polyclonal to Cobra venom - Fab Fragment ( Abpromise for all tested applications). Antigen: Snake Venom of N. naja arta...
LIGHT DIAGNOSTICS Echovirus Blend Reagent, ~50 tests, included in kit #3340 & #3365...
ICAD / DFF45 (NT) Affinity Purified Polyclonal Antibody...
Biology Products: